Why the study?
Does altering MBNL1 concentration affect alternative splicing events in a dose-dependent manner to serve as biomarkers for myotonic dystrophy?
Does altering MBNL1 concentration affect alternative splicing events in a dose-dependent manner to serve as biomarkers for myotonic dystrophy?
A framework based on dose-dependent alternative splicing responses to MBNL1 can estimate functional MBNL concentration and serve as a biomarker for myotonic dystrophy severity.
May support MBNL1 splicing biomarkers in dystrophy models; leaves open human validation and clinical utility.
Alternative splicing is a regulated process that results in expression of specific mRNA and protein isoforms. Alternative splicing factors determine the relative abundance of each isoform. Here we focus on MBNL1, a splicing factor misregulated in the disease myotonic dystrophy. By altering the concentration of MBNL1 in cells across a broad dynamic range, we show that different splicing events require different amounts of MBNL1 for half-maximal response, and respond more or less steeply to MBNL1. Motifs around MBNL1 exon 5 were studied to assess how cis-elements mediate the MBNL1 dose-dependent splicing response. A framework was developed to estimate MBNL concentration using splicing responses alone, validated in the cell-based model, and applied to myotonic dystrophy patient muscle. Using this framework, we evaluated the ability of individual and combinations of splicing events to predict functional MBNL concentration in human biopsies, as well as their performance as biomarkers to assay mild, moderate, and severe cases of DM.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: